The retrospective cohort study analyzed data from 195 colorectal cancer patients who underwent curative surgery following neoadjuvant immune checkpoint inhibitor therapy. The researchers, led by Bo Liu and Bo Li with corresponding authors Jinzhu Zhang, Xueqiang Jian and Zhanlun Liu, examined the relationship between lymph node yield, the total number of lymph nodes retrieved and examined by the pathologist after surgery, and postoperative recurrence. Their central finding was striking: patients with a lymph node yield of twenty or more nodes had significantly poorer recurrence-free survival than patients with lower yields. This association persisted across subgroup analyses stratified by pathological tumor stage, microsatellite status, the type of immune checkpoint inhibitor used, and the neoadjuvant treatment strategy, indicating that the signal was not confined to a narrow slice of the patient population.

To understand why this finding matters, it helps to consider the biology of tumor-draining lymph nodes. These are the lymph nodes that receive drainage from the tumor site, and they are far more than passive filters. They are active immunological hubs where dendritic cells present tumor antigens to naive T cells, where anti-tumor immune responses are primed, and where the immune system mounts its organized defense against cancer. Immune checkpoint inhibitors, drugs that unleash T cells by blocking inhibitory receptors such as PD-1, depend heavily on this lymph node machinery. In many cancers, the response to checkpoint blockade is initiated in the tumor-draining lymph nodes, where T cells are activated and then traffic to the tumor to do their work. Removing these nodes, therefore, might not be an immunologically neutral act.

The study’s single-cell analysis adds a fascinating layer to the story. The researchers performed single-cell RNA sequencing and T-cell receptor sequencing on tumor tissue, peripheral blood, and tumor-draining lymph node samples from colorectal cancer patients. This allowed them to track individual immune cells and, crucially, to identify which T cells in the tumor were clonally related to T cells in the lymph nodes, meaning they shared identical T-cell receptor sequences and therefore descended from the same activated precursor cells. What they found was that patients treated with immune checkpoint inhibitors exhibited a higher frequency of clonally shared CD8-positive effector memory T cells between the tumor-draining lymph nodes and the tumor tissue itself.

This clonal sharing is direct evidence of immunological connectivity between the lymph nodes and the tumor. It suggests that T cells activated in the tumor-draining lymph nodes, under the stimulus of checkpoint blockade, are physically migrating to the tumor and participating in the anti-cancer attack. In other words, the lymph nodes are not just staging grounds for the immune response; they are functioning as the factories that produce the tumor-fighting T cell army that immunotherapy mobilizes. When surgeons remove twenty or more of these nodes, they may be inadvertently dismantling a critical component of the patient’s own anti-tumor immune infrastructure at precisely the moment when immunotherapy has primed it for action.

The clinical implications are potentially significant, though the researchers are careful to note the limits of what their study can establish. As a retrospective cohort study, it demonstrates association rather than causation. It is possible that higher lymph node yield is a marker of more extensive disease or more aggressive surgical practice rather than a direct cause of recurrence. Patients with more nodes removed may have had more advanced disease that prompted wider dissections, or surgeons who remove more nodes may differ systematically in ways that affect outcomes. The authors themselves acknowledge that the mechanisms underlying the association remain unclear and warrant further investigation. Nevertheless, the consistency of the finding across multiple subgroup analyses, and its alignment with a plausible biological mechanism supported by the single-cell data, gives the result a credibility that demands attention.

The finding also sits within a broader and sometimes contentious debate in surgical oncology about the optimal extent of lymphadenectomy. In colorectal cancer, guidelines typically recommend examining at least twelve lymph nodes to ensure accurate staging, since understaging can lead to inadequate adjuvant treatment decisions. Lymph node yield has historically been used as a quality metric for both surgery and pathology, with higher yields generally interpreted as evidence of more thorough cancer care. The new study does not necessarily overturn that logic for patients who do not receive neoadjuvant immunotherapy, but it raises the provocative possibility that the optimal surgical strategy may differ depending on whether a patient’s immune system has been pharmacologically primed before the operation.

Neoadjuvant immunotherapy itself is a rapidly expanding approach in colorectal cancer, particularly for patients with mismatch repair-deficient or microsatellite instability-high tumors, which are exquisitely sensitive to checkpoint blockade. In these patients, preoperative immunotherapy can produce pathological complete responses, allowing some to avoid radical surgery altogether. As the use of neoadjuvant immunotherapy grows, questions about how to adapt standard surgical techniques become increasingly urgent. If tumor-draining lymph nodes are essential partners in the immunotherapy response, as this study’s single-cell data suggest, then the standard practice of extensive lymph node dissection may need to be re-evaluated in this specific patient population, balancing the staging benefits of node removal against the potential immunological cost.

The study also highlights the power of single-cell technologies to illuminate questions that traditional pathology cannot answer. By combining T-cell receptor sequencing across multiple tissue compartments, the researchers were able to visualize the traffic of immune cells between lymph nodes and tumors in a way that would have been impossible a decade ago. This kind of integrative analysis, linking clinical outcomes with high-resolution immune profiling, represents a model for how surgical oncology questions may be addressed in the future. Rather than asking simply how many nodes to remove, surgeons and oncologists may increasingly ask what immunological functions those nodes are performing and how to preserve them.

For now, the study’s authors urge caution rather than immediate changes to practice. The association between higher lymph node yield and poorer recurrence-free survival in immunotherapy-treated colorectal cancer patients is a hypothesis-generating finding, one that should prompt prospective studies designed to test whether more conservative lymph node management could safely improve outcomes. If those studies confirm the retrospective signal, the implications would extend beyond colorectal cancer to any malignancy treated with neoadjuvant immunotherapy and surgery. What is clear already is that the era of immunotherapy is forcing a re-examination of long-held surgical dogmas, and the humble lymph node, once viewed merely as a structure to be counted and cleared, is emerging as an active and potentially indispensable ally in the fight against cancer.

Subject of Research: The association between lymph node yield and recurrence-free survival in colorectal cancer patients treated with neoadjuvant immune checkpoint inhibitor therapy

Article Title: Higher lymph node yield is associated with increased postoperative recurrence in colorectal cancer treated with neoadjuvant immunotherapy: a retrospective cohort study

Article References: Liu, B., Li, B., Zhang, J., Jian, X., & Liu, Z. (2026). Higher lymph node yield is associated with increased postoperative recurrence in colorectal cancer treated with neoadjuvant immunotherapy: a retrospective cohort study. BMC Cancer. https://doi.org/10.1186/s12885-026-16966-4

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16966-4

Keywords: colorectal cancer, immune checkpoint inhibitors, neoadjuvant immunotherapy, tumor-draining lymph nodes, lymph node yield, recurrence-free survival, single-cell RNA sequencing, T-cell receptor sequencing, CD8 T cells, lymphadenectomy, surgical oncology, tumor immunology

A groundbreaking study spearheaded by Liu et al. leverages combined single-cell RNA sequencing (scRNA-seq) and T cell receptor sequencing (scTCR-seq) to dissect the diversity and functional states of TILs in lung adenocarcinoma (LUAD), a predominant NSCLC subtype. This multidimensional approach offers unprecedented resolution into the cellular heterogeneity and clonal dynamics of TIL populations derived from tumor tissue versus circulating blood, revealing crucial insights into immune cell behaviors that drive tumor progression and response to therapy.

Central to the study’s findings is the unexpected enrichment of naïve CD4+ and effector memory CD8+ T cells within tumor tissue compared with peripheral blood. This observation challenges traditional paradigms that typically emphasize fully differentiated, exhausted T cells prevailing inside tumors. The presence of naïve and effector memory subsets suggests an ongoing recruitment and activation process, potentially sustained by tumor-associated antigen exposure, which may underlie differential treatment responsiveness and immune evasion mechanisms intrinsic to NSCLC.

Delving deeper, the research highlights the activation of distinctive signaling pathways within these TIL populations, with granzyme A (GZMA) emerging as a promising novel diagnostic biomarker. GZMA, a serine protease traditionally implicated in cytolytic activity of CD8+ T cells, appears upregulated, signifying active cytotoxic functions that could be harnessed to predict patient prognosis or monitor therapeutic efficacy. This biomarker’s discovery bolsters the rationale for integrating molecular signatures into personalized treatment regimens.

Intriguingly, the transitional dynamics of immune cells within the tumor stroma were mapped with remarkable clarity through TCR clonal tracking. The study identifies macrophages marked by ferritin light chain (FTL) and dendritic cells expressing AIF1 as key mediators transporting diverse CD3 TCR clones to T cells during the tumor’s dynamic transition phase. This crosstalk suggests these myeloid subsets play pivotal roles in shaping T cell repertoires and sustaining antitumor immunity, underscoring their potential as targets to modulate immune infiltration and activation.

Moreover, a fascinating cellular transition unfolds as cytotoxic CD8+ T cells characterized by NKG7 expression propagate clonal expansions leading to terminally exhausted CD8+ subsets. This exhaustion phenotype, a hallmark of chronic antigen exposure, represents a formidable barrier to effective immunotherapy. Understanding the cellular and molecular circuitry governing this exhaustion cascade provides critical leverage for designing interventions aimed at reinvigorating T cell responses and overcoming immune resistance.

The role of T helper cells within the tumor niche also came into sharp focus, with CXCL13-producing subsets facilitating movement toward regulatory T cells (Tregs) not only in the transitional phase but persisting into expansion phases. This trajectory hints at a complex immunoregulatory network where helper T cells potentially contribute to immunosuppression via Treg recruitment or induction, raising important questions about balancing antitumor immunity against immune tolerance mechanisms within NSCLC tumors.

Complementing these cellular insights, comprehensive expression profiling of key cytokines, immune checkpoint receptors, and their ligands painted a vivid picture of functional interplay within the TIL milieu. Cytotoxic CD8+ T cells exhibited elevated levels of canonical effector molecules such as CCL5 and IFNG, hallmarks of vigorous antitumor activity. Simultaneously, T helper populations expressed immune modulators including FTL, TNFRSF4, and TIGIT, while Tregs notably harbored checkpoints such as CTLA4, TIGIT, and FTL, positioning them at the center of suppressive networks that potentially dampen immune responses and facilitate tumor progression.

Crucially, these molecular signatures and cellular behaviors were consistent across both primary and metastatic tumor stages, implying conserved immunological mechanisms throughout disease evolution. This consistency offers a blueprint for therapeutic interventions aimed at multiple stages of NSCLC, emphasizing the utility of targeting shared pathways to overcome immune suppression and improve clinical outcomes.

The implications of these findings extend beyond mere academic curiosity. By dissecting TIL heterogeneity and revealing critical checkpoints in immune cell recruitment, activation, and exhaustion, this research paves the way for refined patient stratification and personalized immunotherapies that can intelligently harness or modulate immune landscapes. The identification of GZMA as a diagnostic biomarker, for instance, suggests new modalities for patient monitoring, while insights into T cell clonal migration underscore the importance of considering spatial dynamics within the tumor microenvironment.

In a broader context, the study exemplifies the power of integrating scRNA-seq and scTCR-seq technologies to resolve cellular phenotypes and functional states with unparalleled granularity. Such approaches are poised to revolutionize cancer immunology, enabling researchers and clinicians alike to unlock the full potential of the immune system in combating malignancies previously deemed intractable.

The elucidation of macrophage and dendritic cell roles in antigen presentation and TCR clone distribution challenges the traditional view of these myeloid cells as mere bystanders, repositioning them as critical conductors of adaptive immune orchestration. Therapeutic strategies harnessing these populations, whether via modulation of antigen-presenting capacities or remodeling of the tumor microenvironment, could synergize effectively with existing TIL-based therapies to amplify antitumor responses.

Perhaps most compellingly, the trajectory from cytotoxic to terminally exhausted CD8+ T cells mapped via NKG7 expression offers a tangible target to prevent or reverse immune dysfunction. Coupled with checkpoint expressions in T helper and regulatory T cells, combinatorial blockade or agonism interventions could be rationally designed to restore immune vigor, surmount resistance mechanisms, and extend patient survival.

Ultimately, this study by Liu and colleagues stands as a landmark contribution to cancer immunology, delivering a comprehensive, single-cell resolution atlas of TILs in NSCLC. It champions precision medicine approaches by coupling molecular diagnostics with immune landscape profiling and opens vistas for innovative therapeutic development. As the fight against lung cancer intensifies, such detailed characterizations of immune milieu will be integral to transforming patient outcomes and enshrining immunotherapy as the cornerstone of oncologic care.

Ongoing and future investigations building on these findings are eagerly anticipated to validate and expand upon this immune atlas, potentially integrating multi-omics data, spatial transcriptomics, and functional assays to fully capture the complexity of tumor-immune interactions. By unraveling the labyrinth of TIL heterogeneity and functional states, the path toward tailored, efficacious therapies for NSCLC patients grows ever clearer.

—

Subject of Research: Characterization and functional profiling of tumor-infiltrating lymphocytes in Non-small Cell Lung Cancer through combined single-cell RNA and T cell receptor sequencing.

Article Title: Characterizing the immune landscape of tumor-infiltrating lymphocytes in non-small cell lung cancer.

Article References:
Liu, JG., Yu, L., Guo, XL. et al. Characterizing the immune landscape of tumor-infiltrating lymphocytes in non-small cell lung cancer. Genes Immun (2025). https://doi.org/10.1038/s41435-025-00330-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41435-025-00330-w